Issue link: https://viewer.e-digitaledition.com/i/746097
A Team of Experts PART OF IMPLEMENTING the strategies to deliver high-quality lung cancer care is bringing on the right team of experts to see that vision through. At NewYork- Presbyterian/Lawrence Hospital, that team includes, among many others, an interventional radiologist, a thoracic surgeon, and medical and radiation oncolo- gists who specialize in thoracic malignancies. Roy Oommen, MD, MBA Thoracic surgeon Roy Oommen, MD, MBA, specializes in the surgical manage- ment of lung cancer and minimally invasive esophageal surgery. He joined the NewYork-Presbyterian team in January 2016 and now offers services at NYP/ Lawrence Hospital as well as NewYork-Presbyterian/Hudson Valley Hospital and NewYork-Presbyterian/Columbia University Medical Center. Dr. Oommen completed his residency in cardiothoracic surgery at Montefiore Medical Center/Albert Einstein College of Medicine and a fellowship in minimally invasive thoracic surgery at Boston Medical Center. He is a recipient of the Robert Grossman, MD, Award for Surgical Excellence. Stephen Reis, MD Interventional radiologist Stephen Reis, MD, joined the NYP/Lawrence Hospital team in June 2016. Prior to helping build the interventional radiology program at NYP/Lawrence Hospital, he worked as an interventional radiologist and attending physician in Dallas at the University of Texas Southwestern Medical Center. Dr. Reis is a member of the American College of Radiology, the Society of Interventional Radiology and the Radiological Society of North America. He has many publications and has been recognized for excellence in teaching interventional radiology fellows since 2013. He continues this role as an Assistant Professor of Interventional Radiology at CUMC. Stephanie Smith-Marrone, MD Thoracic medical oncologist Stephanie Smith-Marrone, MD, with NewYork- Presbyterian Medical Group/Westchester, came to NYP/Lawrence Hospital in April 2016, where she serves as an attending physician for the hematology/oncol- ogy team and Director of the Cancer Clinical Trials Program. Prior to joining NYP/ Lawrence Hospital, she worked at Memorial Sloan Kettering Cancer Center as a medical oncologist specializing in thoracic and head and neck malignancies. Dr. Smith-Marrone is an Assistant Professor of Medicine at CUMC, where she actively participates in clinical conferences. She is board-certified in medical oncology and is a member of the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer. Henry J. Lee, MD, PhD Radiation oncologist Henry J. Lee, MD, PhD, is the new Director of Radiation Oncology at NYP/Lawrence. He joined the team last December. Providing clinical oversight for the delivery of radiation services for the first time on campus, Dr. Lee is also an Assistant Professor of Radiation Oncology at CUMC. He received his medical degree and PhD in neurobiology from the University of Chicago and completed a fellowship in radiation oncology at Memorial Sloan Kettering. Ralph Binder, MD Rounding out the team is longtime NewYork-Presbyterian Medical Group/ Westchester pulmonologist Ralph Binder, MD. Board-certified in pulmonary disease and internal medicine, Dr. Binder has been on staff at NYP/Lawrence since 1982. He received his medical degree from the Yale University School of Medicine and a master of public health degree from Yale's School of Epidemiology and Public Health. traditiona l chemotherapy, genetica lly ta rgeted d r ugs a nd newer i m muno- therapy agents. Access to some of the latest clinica l tria ls in lung ca ncer is available through the academic partner- ship with N Y P/Columbia Universit y Medica l Center in Manhattan. "Today, traditiona l chemotherapy is only one method of lung cancer treat- ment. In the past decade, there have been tremendous adva nces in lung ca ncer research," notes Dr. Smith-Marrone. "We now have drugs which ta rget specific mutations in the cancer cells' DNA and lead to better outcomes for patients, with improved qua lity of life." The a¦liation between the Patholog y laborat or ies at N Y P/ Law rence a nd Columbia a l lows sea m less access to testing tissue samples from lung cancer patients for over 400 genes. Depending on those results, Dr. Smith-Marrone can develop persona lized treatment plans. " L i k e w i s e , i m m u n o t h e r a p y h a s revolutionized the way we approach lung cancer treatment," she says. FDA- approved i m munot herapy dr ugs for lung cancer are o ered in the Hospital's infusion room, and fast-track access to new clinical trial options at Columbia is available for patients who may be eligible. " Th is is a n exciti ng ti me for lu ng ca nc er re sea rch a nd pat ient ca re," Dr. Sm it h-Ma r rone a dd s. "At N Y P/ L aw r enc e , we h ave t he a d v a nt a ge of of fering a comprehensive a rray of sophisticated treatment options within a persona lized setting. W hen patients walk in, they know the team at the desk, a nd the nurses know them a nd their stories. And yet, we can o er extremely innovative approaches to lung cancer with a progra m desig ned specifica lly to meet their needs before, during and after treatment." Among the top priorities of the new collaboration between NYP/Lawrence a nd C olu m bi a Un iver s it y Me d ic a l Center is bringing radiation therapy to lower Westchester. "This is a huge benefit to our commu- nity because most lung cancer patients require radiation as part of their initia l therapy," says Henr y J. Lee, MD, PhD, D i r e c t or of R a d i at ion O nc olog y at 0 9 M D N E W S .C O M /// M D N E W S L O W E R H U D S O N / B R O N X ■ 2 016

